Guardant Health (NASDAQ:GH) Director Medina Manuel Hidalgo Sells 1,300 Shares

Key Points

• Director Medina Manuel Hidalgo sold 1,300 shares on March 6 at an average price of $91.54 for $119,002, leaving him with 1,193 shares—a 52.15% reduction in his holding.
• Guardant reported Q4 EPS of ($0.50), missing estimates by $0.07, while revenue of $281.27 million beat expectations and rose 39.4% year-over-year.
• The stock traded near $91.20 with a market cap of about $11.96 billion; analysts hold a consensus "Moderate Buy" with an average target of $122.57 and institutions own roughly 92.6% of shares.

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Medina Manuel Hidalgo sold 1,300 shares of the business's stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $91.54, for a total transaction of $119,002.00. Following the transaction, the director owned 1,193 shares of the company's stock, valued at approximately $109,207.22. This represents a 52.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Guardant Health Price Performance

GH remained flat at $91.20 during mid-day trading on Monday. 1,712,241 shares of the company's stock traded hands, compared to its average volume of 2,059,165. The business's fifty day simple moving average is $105.09 and its two-hundred day simple moving average is $89.33. The firm has a market cap of $11.96 billion, a price-to-earnings ratio of -27.55 and a beta of 1.67. Guardant Health, Inc. has a 12 month low of $34.88 and a 12 month high of $120.74.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.07). The company had revenue of $281.27 million for the quarter, compared to analyst estimates of $269.74 million. The firm's quarterly revenue was up 39.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.62) EPS. As a group, analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Institutional Investors Weigh In On Guardant Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mcguire Capital Advisors Inc. acquired a new position in shares of Guardant Health during the 4th quarter worth about $155,000. Hamilton Wealth LLC bought a new position in Guardant Health in the fourth quarter valued at approximately $3,859,000. Mercer Global Advisors Inc. ADV grew its stake in Guardant Health by 12.7% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 4,357 shares of the company's stock valued at $445,000 after purchasing an additional 490 shares in the last quarter. Mackenzie Financial Corp increased its position in shares of Guardant Health by 57.6% during the 4th quarter. Mackenzie Financial Corp now owns 36,023 shares of the company's stock worth $3,617,000 after purchasing an additional 13,172 shares during the last quarter. Finally, Fuller & Thaler Asset Management Inc. increased its position in shares of Guardant Health by 3.0% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company's stock worth $249,398,000 after purchasing an additional 72,162 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on GH shares. Robert W. Baird initiated coverage on Guardant Health in a research report on Tuesday, February 17th. They issued an "outperform" rating and a $120.00 price objective for the company. Morgan Stanley upped their price target on shares of Guardant Health from $105.00 to $130.00 and gave the company an "overweight" rating in a report on Monday, December 1st. Evercore set a $110.00 price objective on shares of Guardant Health in a report on Friday, February 20th. Barclays reaffirmed an "overweight" rating and issued a $130.00 target price on shares of Guardant Health in a research note on Friday, February 20th. Finally, Piper Sandler boosted their price target on Guardant Health from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Tuesday, February 24th. Twenty-one investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $122.57.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.